Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 4/20 | 0.52 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.48 |
| ▸ | TYMP | P19971 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALB | P02768 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | GSK3A | P49840 | 2/20 | 0.45 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15257779 | 0.89 | ADORA2A (0.49) | ADORA2AP2RX3TYMPALDH1A1LMNA | |
| SCHEMBL13559231 | 0.88 | ADORA2A (0.66) | ADORA2AP2RX3ALDH1A1LMNAALB | |
| SCHEMBL17955705 | 0.88 | ADORA2A (0.66) | ADORA2AP2RX3ALDH1A1LMNAALB | |
| SCHEMBL12149438 | 0.88 | ADORA2A (0.66) | ADORA2AP2RX3ALDH1A1LMNAALB | |
| SCHEMBL13559257 | 0.88 | ADORA2A (0.66) | ADORA2AP2RX3ALDH1A1LMNAALB | |
| SCHEMBL15259226 | 0.85 | ADORA2A (0.52) | ADORA2AGSK3ARPS6KA3MAPK14ADORA3 | |
| SCHEMBL15045902 | 0.85 | ADORA2A (0.52) | ADORA2AGSK3ARPS6KA3MAPK14ADORA3 | |
| SCHEMBL17232109 | 0.84 | ADORA2A (0.48) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL16330660 | 0.83 | ALDH1A1 (0.52) | ADORA2AP2RX3TYMPALDH1A1LMNA | |
| SCHEMBL15045986 | 0.83 | P2RX3 (0.45) | P2RX3TYMPALDH1A1LMNAALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160129122-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2016-05-12 | — | — | US | disclosed |
| US-20140288025-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2014-09-25 | — | — | US | disclosed |
| US-20130244966-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| WO-2013090420-A2 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2013-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130244966-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | FABP1, FABP2, HAVCR2 | ADORA2A 645/4885P2RX3 4078/4885TYMP 1914/4885 |
| US-20140288025-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | FABP1, FABP2, HAVCR2 | ADORA2A 645/4885P2RX3 4078/4885TYMP 1914/4885 |
| US-20160129122-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | FABP1, FABP2, HAVCR2 | ADORA2A 645/4885P2RX3 4078/4885TYMP 1914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.